The next generation MOSkin dosimeter is the only medical radiation sensor technology in the world that accurately measures individual radiation doses and dose rates, in real time, at precisely defined and reproducible skin tissue and organ depth for the global $35 billion radiotherapy for cancer treatment, angiography equipment and CT and Xray scan markets.Electrogenics Laboratories Ltd (ELL), was formed in 2019 to commercialise this breakthrough, patented technology developed by the Centre for Medical Radiation Physics (CMRP), University of Wollongong (UOW), Australia. It has been fully tested and proven with over $8 million of grant funding in over 20 hospitals and clinics including Australia, Brazil, Italy, Malaysia and China.The ELL senior management and support staff team provide extensive experience in advanced technology product development and international business development to rapidly drive MOSkin to full global commercialisation and distribution. Distinguished Professor Anatoly Rozenfeld, Professor Michael Lerch, and Associate Professor Marco Petasecca from UOW are ELL's scientific advisors. Point Blank Medical has been appointed exclusive Australian distributors. Transmedic Group has been exclusively appointed for the ASEAN and Hong Kong markets. Russian distribution is currently under negotiation. Australian development partners including Genesys Electronics Design, Design & Industry and Brandwood Biomedical will support the technical and regulatory requirements of the MOSkin technology for rapid commercialisation. ELL's goal is to become the world leader in the development and provision of cutting edge, next generation radiation dosimetry solutions. The initial market sector is radiotherapy for cancer patients with an estimated market potential of US$950 million.

Website: electrogenicslabs.com

Employees: 5 - 9

HQ: N/A

Location: Sydney, N/A, AU

Revenue: Not Available

Are you looking for the contact details of Electrogenics Laboratories Limited? ConnectPlex is the right place to be! With our extensive database of company information, we can help you get in touch with key decision-makers and professionals within the company. Our platform allows you to search for company contacts by name, job title, department, and more, making it easy to find the right person to connect with. Whether you're looking to collaborate on a project, discuss a business opportunity, or simply get more information about Electrogenics Laboratories Limited, ConnectPlex can help you get started. Our platform is designed to make B2B lead generation easy and efficient, saving you time and resources in your search for the right contacts. Start your search today and connect with the people who matter most to your business!

Electrogenics Laboratories Limited is a medical technology company based in Sydney, Australia, that specializes in developing and commercializing cutting-edge radiation dosimetry solutions. The company's flagship product, the MOSkin dosimeter, is a revolutionary medical radiation sensor technology that accurately measures individual radiation doses and dose rates in real-time, at precisely defined and reproducible skin tissue and organ depths. This technology has been fully tested and proven with over $8 million of grant funding in over 20 hospitals and clinics across the globe. Electrogenics Laboratories' goal is to become the world leader in the development and provision of next-generation radiation dosimetry solutions, with an initial focus on the radiotherapy market for cancer patients, which has an estimated market potential of US$950 million. The company's senior management and support staff team have extensive experience in advanced technology product development and international business development, which will be instrumental in rapidly driving MOSkin to full global commercialization and distribution. Distinguished Professor Anatoly Rozenfeld, Professor Michael Lerch, and Associate Professor Marco Petasecca from the University of Wollongong are the company's scientific advisors. Point Blank Medical has been appointed as the exclusive Australian distributor, while Transmedic Group has been exclusively appointed for the ASEAN and Hong Kong markets.

Electrogenics Laboratories Ltd (ELL) has developed a new device called MOSkin that can accurately measure the amount of radiation a person receives during medical treatments like cancer treatment, angiography, and CT and X-ray scans. This device is the only one of its kind in the world that can do this in real time and has been tested in over 20 hospitals and clinics. ELL has a team of experienced professionals who will help bring this product to the global market. They have already partnered with companies in Australia, Brazil, Italy, Malaysia, and China. Their goal is to become the leading company in radiation dosimetry solutions. The device has the potential to make $950 million in the first market sector alone.